PF-06726304 is a selective inhibitor of Histone-lysine N-methyltransferase EZH2 (enhancer of Zeste homolog 2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27) and is amplified and/or overexpressed in several human cancers including breast, prostate and lymphoma. PF-06726304 is a novel structural class of EZH2 inhibitor.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.